Retatrutide vs Tirzepatide vs Semaglutide: Which GLP-1 Is Best in 2026?
Retatrutide vs Tirzepatide vs Semaglutide: 2026 Head-to-Head Comparison
- Most weight loss: Retatrutide — 28.7% at 68 weeks (Phase 3, Dec 2025) vs 22.5% tirzepatide vs 15% semaglutide
- Best tolerability: Tirzepatide — lower GI side effects than both others
- Most approved/established: Semaglutide — longest track record, cardiovascular data, widely available in UAE
- Retatrutide status: Research compound only in 2026 — FDA filing anticipated 2026–2027
- Head-to-head trial (SURMOUNT-5, 2025): tirzepatide outperformed semaglutide by 6.5 percentage points over 72 weeks
Three compounds now define the conversation around pharmacological weight loss research: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and the emerging retatrutide. Each represents a step up in mechanistic complexity — and each delivers meaningfully greater weight reduction than the one before it.
This comparison uses the latest 2025–2026 trial data — including the December 2025 TRIUMPH-4 Phase 3 retatrutide results and the May 2025 SURMOUNT-5 head-to-head tirzepatide vs semaglutide trial — to give UAE researchers the most accurate picture currently available.
Mechanism: What Each Drug Actually Does
Understanding the mechanism explains why the weight loss gap between these three compounds is so large:
| Compound | Receptors Targeted | Primary Effects |
|---|---|---|
| Semaglutide | GLP-1 only | Reduced appetite, slower gastric emptying, improved insulin response |
| Tirzepatide | GLP-1 + GIP | Above + enhanced insulin secretion, improved fat metabolism, better tolerability |
| Retatrutide | GLP-1 + GIP + Glucagon | Above + increased energy expenditure, hepatic fat oxidation, thermogenesis |
The glucagon receptor addition in retatrutide is the key differentiator. While GLP-1 and GIP work primarily by reducing calorie intake (appetite suppression), glucagon receptor agonism actively increases the body's energy expenditure — essentially raising the metabolic rate. The combined effect is both eating less and burning more, which explains why retatrutide's results in trials exceed everything that came before it.
Weight Loss Results: Latest Trial Data (2025–2026)
The Numbers
| Compound | Trial | Duration | Average Weight Loss | Max Dose |
|---|---|---|---|---|
| Retatrutide 12mg | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% (~71 lbs) | 12mg/week SC |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | 22.5% | 15mg/week SC |
| Semaglutide 2.4mg | STEP-1 | 68 weeks | 14.9% | 2.4mg/week SC |
Head-to-Head: Tirzepatide vs Semaglutide (SURMOUNT-5, May 2025)
For the first time, tirzepatide and semaglutide were compared directly in a randomised controlled trial. SURMOUNT-5 results (May 2025) showed tirzepatide produced 6.5 percentage points more weight loss than semaglutide over 72 weeks. A separate systematic review found patients on tirzepatide were 2.28 times more likely to achieve ≥20% weight loss compared to semaglutide.
No head-to-head trial yet exists between retatrutide and the other two — retatrutide trials compare against placebo only. However, the consistently superior results across different trial populations make the comparison directionally clear.
Weight Loss Verdict
Retatrutide > Tirzepatide > Semaglutide — each with a meaningful gap. Retatrutide's 28.7% vs tirzepatide's 22.5% is a ~6 percentage point advantage, mirroring tirzepatide's advantage over semaglutide.
Side Effects and Tolerability
All three compounds produce primarily gastrointestinal side effects during titration. The differences in tolerability are clinically meaningful:
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | High (real-world) | Lower than semaglutide | 47% (Phase 2) |
| Vomiting | Moderate | Lower than semaglutide | 23% (Phase 2) |
| Diarrhoea | Moderate | Similar to semaglutide | 19% (Phase 2) |
| Discontinuation (AEs) | ~7% (STEP-1) | ~6% (SURMOUNT-1) | 12–18% (TRIUMPH-4) |
| Unique signals | Pancreatitis risk (rare) | None notable | Dysaesthesia (Phase 3) |
Tirzepatide's GIP receptor component appears to counteract some of semaglutide's GI discomfort — making it paradoxically the best-tolerated compound despite producing more weight loss. Retatrutide's higher discontinuation rate (up to 18.2% at 12mg) reflects its more aggressive mechanism. The new dysaesthesia signal from TRIUMPH-4 is being monitored but has not halted development.
Tolerability Verdict
Tirzepatide wins — better tolerability than semaglutide despite superior efficacy. Retatrutide has the highest side effect burden, though substantially lower in patients with BMI ≥35 (12.1% discontinuation vs 18.2% overall).
FDA Approval and UAE Availability
| Compound | FDA Status | UAE Availability | Price (UAE, 2026) |
|---|---|---|---|
| Semaglutide | Approved (Ozempic 2021, Wegovy 2021) | Prescription via clinics & pharmacies | AED 800–1,500/month |
| Tirzepatide | Approved (Mounjaro 2022, Zepbound 2023) | Prescription via clinics & pharmacies | AED 1,000–2,000/month |
| Retatrutide | Phase 3 (filing ~2026–2027) | Research compound only | AED 700–1,100/vial (research) |
For UAE residents, semaglutide and tirzepatide are available via prescription from endocrinology clinics and licensed medical centres. Retatrutide is available only as a research-grade compound while its Phase 3 programme completes. For sourcing details, see our Buy Retatrutide UAE guide and our Retatrutide Complete Guide.
Which Should UAE Researchers Choose?
Choose Semaglutide If
- You want the most established long-term safety data (5+ years real-world use)
- Cardiovascular protection is a primary research interest — SUSTAIN-6 and SELECT trials show significant CV risk reduction
- Budget is a primary constraint — tends to be lowest priced of the three
- You or your research subject has type 2 diabetes as well as obesity
Choose Tirzepatide If
- You want the best current balance of efficacy, tolerability, and approval status
- GI side effects were problematic on semaglutide — tirzepatide is better tolerated
- Research target is ≥20% weight loss — tirzepatide outperforms semaglutide significantly here
- Most specialists consider tirzepatide the preferred front-line choice for new patients starting in 2026
Choose Retatrutide If
- Maximum weight loss is the primary research objective and side effects are acceptable
- You are researching the glucagon receptor pathway or triple agonism specifically
- Research subjects have reached a plateau on tirzepatide or semaglutide
- You understand this is an unapproved investigational compound with evolving Phase 3 data
Frequently Asked Questions
Which causes more weight loss — retatrutide, tirzepatide, or semaglutide?
Retatrutide leads with 28.7% average weight loss at 68 weeks (TRIUMPH-4, December 2025). Tirzepatide achieves approximately 22.5% (SURMOUNT trials, 72 weeks). Semaglutide averages 14.9% at 68 weeks. Each step up in receptor complexity translates directly to meaningfully greater weight reduction.
Is tirzepatide better than semaglutide?
Yes, by a significant margin confirmed in a head-to-head trial. SURMOUNT-5 (May 2025) showed tirzepatide produced 6.5 percentage points more weight loss than semaglutide over 72 weeks. Patients on tirzepatide were 2.28 times more likely to achieve ≥20% weight loss. Tirzepatide is also better tolerated despite being more effective.
Which has the fewest side effects?
Tirzepatide has the best tolerability of the three — lower GI side effect rates than semaglutide despite stronger efficacy, likely because GIP receptor agonism counteracts GLP-1-driven nausea. Retatrutide has the highest side effect burden, with 12–18% discontinuation due to adverse events in Phase 3, plus the newly identified dysaesthesia signal.
Is retatrutide available in the UAE in 2026?
Retatrutide is available as a research compound from UAE peptide suppliers — it has not received FDA or UAE regulatory approval. Tirzepatide and semaglutide are both available by prescription in the UAE via licensed medical clinics and pharmacies.
When will retatrutide be approved?
FDA filing is anticipated in 2026–2027 after the remaining six to seven TRIUMPH Phase 3 readouts complete. Approval is expected mid-to-late 2027. UAE prescription availability would follow approximately 12–18 months later, around 2028–2029.
Research-Grade Peptides for UAE Researchers
CoreSup supplies verified research compounds including retatrutide, with third-party COA documentation and UAE-wide delivery.
View Peptide Collection →
